纤溶酶原激活剂与抑制剂检测对恶性肿瘤诊断的临床价值  

THE CLINICAL VALUE OF DETECTING BLOOD PLASMINOGEN ACTIVATOR AND INHIBITOR IN CANCER PATIENTS

作　　者：闫海润[1] 金春明[1] 仝连信[1] 黄永存[1] 姜蕾[1] 金大伟[1] 鞠传余[1] 

机构地区：[1]牡丹江医学院附属红旗医院检验科,黑龙江牡丹江157011

出　　处：《牡丹江医学院学报》2011年第4期36-38,共3页Journal of Mudanjiang Medical University

基　　金：黑龙江省教育厅科研项目(11541385)

摘　　要：目的:探讨恶性肿瘤患者血液纤溶酶原激活剂与抑制剂检测的临床应用价值。方法:检测185例恶性肿瘤患者血液纤溶酶原激活剂(t-PA)﹑纤溶酶原抑制剂(PAI-1)活性变化,对检测数据进行统计学分析。结果:不同类型的恶性肿瘤患者与正常对照组t-PA及PAI-1比较差异有统计学意义(p<0.05)。应用全自动血凝仪底物发光法检测恶性肿瘤患者纤溶活性变化具有敏感性﹑特异性﹑准确性高的优点。结论:检测t-PA及PAI-1活性变化,从而判断恶性肿瘤细胞侵润﹑增殖﹑转移及出血﹑血栓形成的原因。Objective：To discuss the clinical value of detecting blood plasminogen activator and inhibitor in cancer patients. Methods：Activity of blood plasminogen activator and inhibitor was detected in 185 cases cancer patients, and the date were statistically analyed. Results： There were significant differences in t - PA and PAI- 1 levels between the normal group and different types of cancer patients （ p 〈 0.05 ）. The sensitivity, specificity and accuracy of fibrinolytic activity detected with the automated blood analyzer chemiluminescence substrate were higher than those of routine test. Conclusion ：The detecting of activity of t - PA and PAI- 1 contributes to determine the reasons for the invasion of malignant cells , Proliferation , metastasis and the bleeding, thrombosis.

关 键 词：纤溶酶原激活剂 纤溶酶原抑制剂 肿瘤 底物发光法 

分 类 号：R973.2[医药卫生—药品]